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In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell
transplantation (HCT) as consolidation of a ﬁrst remission in patients with multiple myeloma (MM) is well
established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied
in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the
Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Trans-
plantation, and the European Society of Blood and Marrow Transplantation convened a meeting of
MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM
patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM,
(3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move
the research agenda forward. After reviewing the available data, the expert committee came to the following
consensus statement for salvage autologous HCT: (1) In transplantation-eligible patients relapsing after
primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage
therapy should be considered standard; (2) High-dose therapy and autologous HCT should be considered
appropriate therapy for any patients relapsing after primary therapy that includes an autologous HCT with
initial remission duration of more than 18 months; (3) High-dose therapy and autologous HCT can be used as
a bridging strategy to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in
the context of well-designed prospective trials that should include new agents, such as monoclonal anti-
bodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous HCT consolidation should
be explored as a strategy to develop novel conditioning regimens or post-HCT strategies in patients with short
(less than 18 months remissions) after primary therapy; and (6) Prospective randomized trials need to be
performed to deﬁne the role of salvage autologous HCT in patients with MM relapsing after primary therapy
comparing it to “best non-HCT” therapy. The expert committee also underscored the importance of collecting
enough hematopoietic stem cells to perform 2 transplantations early in the course of the disease. Regarding
allogeneic HCT, the expert committee agreed on the following consensus statements: (1) Allogeneic HCT
should be considered appropriate therapy for any eligible patient with early relapse (less than 24 months)
after primary therapy that included an autologous HCT and/or high-risk features (ie, cytogenetics, extra-
medullary disease, plasma cell leukemia, or high lactate dehydrogenase); (2) Allogeneic HCT should be
performed in the context of a clinical trial if possible; (3) The role of postallogeneic HCT maintenance therapy
needs to be explored in the context of well-designed prospective trials; and (4) Prospective randomized trials
need to be performed to deﬁne the role salvage allogeneic HCT in patients with MM relapsing after primary
therapy.
 2015 American Society for Blood and Marrow Transplantation.
Table 1
Phase II Trials of New Combination Therapies for Relapsed and Refractory
Myeloma
Ref ORR (CR) PFS/OS, mo Comments
Immunomodulatory drug doublets
Thal/Dex [15] 47% (13%) 14/38 RRMM
Len/Dex [16-18] 60.6% (15%) 11/38 RRMM
Pom/Dex [19] 31% (1%) 4/12.7 RRMM
Proteasome inhibitor doublets
Bor/Dex [20] 43% (9%) 6.2/29.8 RRMM
Bor/PegAnthr [21] 44% (4%) 9/NS RRMM
Car/Dex [22] 55% (5%) 7/NS RRMM
Triple drug combinations
VTD [23] 63% (6%) 6/22 RRMM
RVD [24] 61% (8%) 7.7/37 RRMM
CyBor Steroids [25] 95% (NS) NS/NS RRMM
KRD [26] 76.9% (5.7%) 15.4/NS RRMM
Elo Len Dex [27] 82% (4%) NR/NR RRMM
Ref indicates reference; ORR, overall response rate; Thal, thalidomide; Dex,
dexamethasone; RRMM, relapse/refractory multiple myeloma; Len, lenali-
domide; Pom, pomalidomide; Bor, bortezomib; PegAnthr, pegylated
anthracycline; NS, not stated; Car, carﬁlzomib; VTD, bortezomib, thalido-
mide, dexamethasone; RVD, lenalidomide, bortezomib, dexamethasone;
CyBor, cyclophosphamide, bortezomib; KRD, carﬁlzomib, lenalidomide,
dexamethasone; Elo, elotuzumab; NR, not reached.
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Multiple myeloma (MM) is a disease characterized by
malignant plasma cell proliferation, bone destruction, and
immunodeﬁciency. The median age at diagnosis is approxi-
mately 70 years. MM is responsible for about 1% of all cancer-
related deaths in western countries [1].
Modern therapy now includes induction therapy with
combinations of immune-modulatory drugs (IMiDs), such as
thalidomide and lenalidomide, and proteasome inhibitors
(bortezomib and carﬁlzomib) in combination with steroids,
alkylators, or anthracyclines. When possible, patients who
are deemed “transplantation eligible” undergo consolidation
therapy with high-dose melphalan and autologous hemato-
poietic cell transplantation (HCT). This therapeutic strategy
has improved the median overall survival (OS) for patients
with MM from 36 months to more than 5 years in patients
with standard risk MM [2-4].
Despite modern therapy, most patients with MM will live
to see their disease recur. Several prognostic factors for disease
progression have been identiﬁed, such as beta-2 micro-
globulin, albumin (International Staging System [ISS] score),
plasma cell labeling index, elevated serum lactate dehydro-
genase, and certain chromosomal abnormalities, such as
t(4;14) and t(14;16), either partial or complete deletion of
chromosome 17, deletion of 8q21, and 1p loss or 1q gains [5-9].
The availability of both proteasome inhibitors and IMiDs
has led to the development of multiple combination
chemotherapy regimens as salvage therapies that include
different permutations of these drugs. Although response
rates of the combinations are higher, it is uncertain whether
any speciﬁc combination is associated with better survival or
whether sequential therapy would be equally effective [10].
These new combinations have resulted in dramatic OS
improvements for MM patients relapsing after primary
therapy over the last decade. Themagnitude of improvement
was examined by Kumar et al. The median OS after relapse
increased from 11.8 months for patients relapsing before
2000 to 24 months for patients relapsing beyond that date.
The OS beneﬁt was seen primarily in patients receiving 1 of
the IMiDs or proteasome inhibitors. The prognosis for pa-
tients who become resistant to both agents is extremely
poor. Among 286 patients identiﬁed, 74% received subse-
quent therapy (range, 0 to 8), with 44% of patients achieving
at least a minor response. The median OS and event-free
survival from the time of registration were 9 and 5 months,
respectively. These patients have been successfully treated
with novel therapeutic approaches, including carﬁlzomib
and/or pomalidomide, but will invariably succumb to their
disease [10-12].
In contrast to the upfront setting, in which the role of
high-dose therapy as consolidation of a ﬁrst remission is well
established, the role of a second course of high-dose therapy
with autologous or allogeneic HCT has not been extensively
studied. To that effect, the International Myeloma Founda-
tion through its International Myeloma Working Group,
together with the Blood and Marrow Transplant Clinical
Trials Network, the National Marrow Donor Program, the
European Society of Blood and Marrow Transplantation
(EBMT), and the American Society of Blood and Marrow
Transplantation, convened a meeting of MM experts
regarding the role of autologous or allogeneic HCT in the
treatment of patients who had progressed after primary
therapy with or without autologous HCT consolidation. The
goals of the meeting were as follows: Summarize current knowledge regarding the role of
autologous or allogeneic HCT in MM patients pro-
gressing after primary therapy
 Propose guidelines for the use of salvage HCT in MM
 Identify knowledge gaps
 Propose a research agenda
 Develop a collaborative initiative to move the research
agenda forward
Herein are the results of those deliberations held in
Minnesota on October 27, 2014. The meeting was supported
in part by an unrestricted grant from Sanoﬁ Pharmaceuticals
to the International Myeloma Foundation and from the BMT
CTN U01.CURRENT STANDARDS FOR TREATMENT OF RELAPSED
AND/OR REFRACTORY MYELOMA
Before the advent of IMiDs and proteasome inhibitors,
patients with relapsed MM had limited therapeutic options.
Salvage therapy with alkylators, anthracycline, steroids,
vinca alkaloids, or combinations had response rates of 50% or
less with short remission durations and poor prognoses
[13,14]. Salvage therapy for MM has been greatly improved
by the availability of new agents and combinations. Table 1
summarizes the most relevant phase II trials exploring new
combinations of IMiDs and proteasome inhibitors in patients
with relapsed and or refractory MM.
In the last 2 years, 4 randomized trials have been per-
formed and reported assessing optimal treatment of patients
relapsing after 1 to 3 prior lines of treatment. The ﬁrst trial
was reported by Garderet et al. and compared the efﬁcacy
and safety of bortezomib-thalidomide-dexamethasone
versus thalidomide-dexamethasone in patients relapsing
after an autologous HCT. A total of 269 patients were
randomized. Complete remission (CR) and near CR rates
were signiﬁcantly better for bortezomib-thalidomide-
dexamethasone than for thalidomide-dexamethasone (45%
versus 25%), which translated into an superior median time
to progression (19.5 versus 13.8months) and a trend towards
improved 24-month survival (71% versus 65%; P ¼ .093).
Table 2
Results of Phase III Trials Comparing Two to Three Drug Combinations in
Patients with Myeloma Failing One to Three Prior Therapies
Ref ORR (CR) PFS/OS Comments
[28] VTD 88% (28%)
TD 72% (13%)
19.8/NS
13.8/NS
First relapse after autologous
[29] KRD 87% (31.8%)
RD 66.6% (9.3%)
26.3/NR
17.6/NR
1 to 3 prior therapies
[30] Pano Bor Dex 60.7% (NS)
Bor Dex 54.6% (NS)
11.9/NS
8.08/NS
1 to 3 prior therapies
[31] Rev Dex
Rev Dex Elo
14.9/NS
19.4/NS
1 to 3 prior therapies
TD indicates thalidomide, dexamethasone; RD, lenalidomide, dexametha-
sone; Pano Bor Dex, panobinostat, bortezomib, dexamethasone; Bor Dex,
bortezomib, dexamethasone; Rev Dex, lenalidomide, dexamethasone.
Table 3
Retrospective Analysis of Salvage Autologous HCT Outcomes (Series with
More Than 40 Patients)
Ref n NRM
(%)
Median
PFS in
Months
Prognostic Factor
[32] 44 2 12 First RD
[33] 81 3 16 First RD, VGPR
[34] 41 7 8.5 Age > 65, lines of therapy
[35] 55 5 14 First RD
[36] 83 NS 15.6 NS
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thrombocytopenia were signiﬁcantly higher in the
bortezomib-thalidomide-dexamethasone arm [28].
Stewart et al. reported the results of a randomized trial of
carﬁlzomib, lenalidomide, and dexamethasone versus lena-
lidomide and dexamethasone in patients with MM failing 1
to 3 prior therapies (ASPIRE Trial). ASPIRE enrolled 792 pa-
tients with relapsed or refractory MM. The objective
response rate was 87% for carﬁlzomib, lenalidomide, and
dexamethasone versus 67% for lenalidomide and dexa-
methasone, with a signiﬁcantly higher rate of CRs in the
carﬁlzomib, lenalidomide, and dexamethasone arm (32%
versus 9%; P< .0001). Median progression-free survival (PFS)
in the carﬁlzomib, lenalidomide, and dexamethasone arm
was 26.3 months versus 17.6 months for the lenalidomide
and dexamethasone arm. Median OS has not been reached in
either group, but there was a trend toward longer survival in
the carﬁlzomib arm [29].
San Miguel et al. reported the results of a phase III trial
comparing panobinostat, bortezomib, and dexamethasone to
bortezomib and dexamethasone in patients with MM failing
1 to 3 prior therapies. Of 768 randomized patients, 387
received panobinostat, bortezomib, and dexamethasone and
382 received placebo, bortezomib, and dexamethasone.
Panobinostat, bortezomib, and dexamethasone showed su-
perior PFS when compared with placebo, bortezomib, and
dexamethasone (12.0 versus 8.1 months; hazard ratio, .63; P
< .0001) with no OS difference reported. Complete plus near
complete response rates were 28% and 16%, with median
response duration of 13.1 and 10.9 months, respectively [30].
Lonial et al. reported the results of a phase III trial
comparing the combination of elotuzumab plus lenalido-
mide plus dexamethasone to placebo plus lenalidomide plus
dexamethasone (Eloquent 2) [31]. Overall, 321 patients were
assigned to the elotuzumab group and 325 to the control
group. After a median follow-up of 24.5 months, the rate of
PFS at 1 year in the elotuzumab group was 68% compared
with 57% in the control group; at 2 years, the rates were 41%
and 27%, respectively. Median PFS in the elotuzumab group
was 19.4 months versus 14.9 months in the control group
(hazard ratio for progression or death in the elotuzumab
group, .70; 95% conﬁdence interval, .57 to .85; P < .001).
Therefore, by the end of 2015, the MM community has
completed 4 randomized trials in patients with relapsed MM
(failing 1 to 3 prior therapies) in which all of those reported
to date have demonstrated that more intense therapy (trip-
lets versus doublets) is associated with improvements in
depth of response, and that depth of response is associated
with improvements in PFS although a deﬁnitive survival
beneﬁt has not been shown. These results are summarized in
Table 2.
With the increasing efﬁcacy of salvage therapy for MM,
the role of high-dose therapy with HCT support (so-called
salvage HCT) to further enhance the depth of response is
being increasingly explored and formed the basis of discus-
sion for the expert committee.[37] 60 NS 11 NS
[38] 98 4 10.3 First RD
[39] 187 2 11 First RD
[40] 200 3 15 First RD, reinduction with novel
drugs and response, ISS at salvage
autologous HCT
[41] 111 NS 18 Improved outcomes for second HCT when
compared with IMiDs and proteasome
inhibitors, stage, hemoglobin
RD indicates remission duration; VGPR, very good partial response.WHAT IS THE DEFINITION OF SALVAGE HCT?
For the purpose of discussion, the expert committee
deﬁned salvage HCTas either an autologous or allogeneic HCT
performed on MM patients who had failed a prior line of
therapy. The committee recognized that this deﬁnition
would encompass multiple scenarios, ranging from trans-
plantation-naïve patients failing frontline treatment topatients who had failed multiple therapies without ever
having an HCT.
ROLE OF AUTOLOGOUS HCT AS TREATMENT FOR
PATIENTS RELAPSING AFTER PRIMARY THERAPY IN
TRANSPLANTATION-NAÏVE PATIENTS
The optimal treatment for transplantation-eligible pa-
tients who relapsed after an initial therapy that did not
include high-dose therapy consolidation remains uncertain,
although it is the comparator arm for all randomized trials of
early versus delayed HCT. Reinduction treatment with com-
bination chemotherapy is the standard and most experts
agreed that high-dose therapy consolidation should be
considered the standard of care at this time for this patient
population. The expert committee agreed that this patient
population, although heterogeneous, is worthy of prospec-
tive trials designed to address the issue of optimal reinduc-
tion therapy and consolidation to determine whether their
natural history is different than that for patients relapsing
after a prior autograft.
ROLE OF AUTOLOGOUS HCT FOR PATIENTS RELAPSING
AFTER PRIOR AUTOGRAFT
Retrospective Trials
To date, multiple reports of salvage autologous HCT have
been published and are summarized in Table 3. In all reports,
chemosensitivity and remission duration after ﬁrst autograft
were the most important prognostic factors for subsequent
long-term disease control. However, it is still uncertain
Figure 1. (A) Number or salvage HCT performed for MM in North America
over time (CIBMTR registry). (B) Type of salvage HCT performed for MM over
time (CIBMTR registry).
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regardless of remission duration. Most reports identiﬁed that
the number of lines of prior therapy had a signiﬁcant impact
on outcomes and suggested that salvage autologous HCT
should not be relegated to a “last-ditch effort” in patients
who have failed all prior therapies, but it should be consid-
ered an integral component of initial salvage strategies.
Of particular importance is the retrospective analysis per-
formed by Grövdal et al. in which treatment outcomes of
1061 consecutive patients from 24 hospitals in Denmark,
Finland, Norway, and Sweden who had received an autolo-
gous HCT as consolidation of a ﬁrst remission were reported.
During the study period, 564 patients progressed and were
treated with either conventional chemotherapy (n ¼ 91);
IMiDs and/or proteasome inhibitors (n ¼ 362), or a second
autologous HCT after either approach (n¼ 111). Patients who
received salvage therapy that included a second HCT had a
statistically signiﬁcantly longer median survival; 4 years
compared with 3.3 years for those who received salvage
therapy with IMiDs and/or proteasome inhibitors but
without a second autologous HCTand 2.5 years for thosewho
received conventional chemotherapy. Of note, in this anal-
ysis, even patients undergoing a second autograft with initial
remission durations of less than 12 months still beneﬁted
from the procedure when compared with the other groups
[41].
Current Activity in North America
Data from the Center for International Blood and Marrow
Transplant Research (CIBMTR) data base show that since
1995, 22,069 MM patients were reported to have relapsed
after autologous HCT. Data regarding salvage HCT were
available on 80% of relapsed patients: most of them (15,529
[87%]) did not receive a subsequent HCT, 1606 (9%) received
another autologous HCT (mostly single,1524 [85%] or rarely a
tandem, 82 [<1%]). Another 624 patients (3.6%) underwent
an allogeneic HCT at some point during their treatment
course as salvage therapy. However, since 2001, there is a
constant increase in the salvage HCT activity, with more than
300 patients per year after 2010 (Figure 1A,B).
Current Activity in Europe
In the EBMT database, since 1995, 33,415 MM patients
were reported to be in ﬁrst relapse after autologous HCT. In
that setting, various salvage treatments were performed:
most of the patients, 26,622 (80%), did not receive a subse-
quent HCT, 5275 (15.8%) received a subsequent autologous
HCT (either 1, 4443 [13.3%], 2, 260 [.8%], or a tandem auto
followed by allogeneic HCT, 572 [1.7%]). Another 1527 pa-
tients (5%) underwent an allogeneic transplantation at 1
point of their treatment course as a salvage therapy. Since
1995, there is a constant increase in the salvage HCT
numbers, reaching more than 500 patients per year after
2012 (Figure 2A,B).
Prospective Trials of Salvage Autologous HCT
The ﬁrst prospective randomized trial studying autolo-
gous HCT versus less-intensive alkylating agent consolida-
tion (weekly cyclophosphamide) after ﬁrst relapse and
reinduction with a bortezomib-containing regimen has been
reported [42]. This multicenter, randomized, open-label,
phase III study recruited patients at least 18 years old with
MM who needed treatment for ﬁrst progressive or relapsed
disease at least 18 months after a previous autologous HCT
from 51 centers across the United Kingdom. Beforerandomization, eligible patients received bortezomib, doxo-
rubicin, and dexamethasone induction therapy and then
underwent peripheral blood stem cell mobilization and
harvesting, if applicable. Eligible patients (with adequate
stem cell harvest) were randomly assigned (1:1) to either
high-dose melphalan 200 mg/m2 plus salvage HCT or to oral
cyclophosphamide (400 mg/m2 per week for 12 weeks). This
trial showed a clear advantage in terms of time to progres-
sion, 19 versus 11 months (P < .0001) for the transplantation
arm compared with the chemotherapy arm and, in fact, the
trial was stopped earlier because it met its predeﬁned
endpoint. However, the control arm is considered nowadays
suboptimal. With limited follow up, an OS difference has not
been shown.
The Nordic group published recently a phase II study
analyzing salvage autologous HCT in 53 bortezomib- and
lenalidomide-naïve patients who previously received 1
autologous HCT [43]. The reinduction was bortezomib based
and the conditioning regimen included bortezomib as well.
The second PFS was similar to the initial PFS, 19 versus 20
months (P ¼ .80). Median OS was almost 5.5 years with
acceptable toxicity [43].
RESULTS OF CONSENSUS SURVEY REGARDING ROLE OF
AUTOLOGOUS HCT IN RELAPSED MYELOMA
Before the consensus conference, participants were asked
to rate their agreement with a variety of statements
Figure 2. (A) Since 1995, evolution of salvage treatment after autologous transplantation in Europe: no transplantation versus autologous transplantation. 2014 data
is incomplete (EBMT registry). (B) Since 1995, evolution of salvage autologous transplantation in Europe: single (AUTO1) versus double (AUTO2) versus tandem auto-
allo (ALLO2). 2014 data is incomplete (EBMT registry).
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agreed with the statement and a score of 10 if they strongly
disagreed.
When asked if salvage autologous HCT should be
considered for all patients relapsing after primary therapy, if
eligible, and with an initial remission duration of more
than 24 months, there was a clear consensus agreement
(Figure 3A). When asked if salvage autologous HCT should be
considered for all patients relapsing after primary therapy, if
eligible, and with an initial remission duration of less than 6
months, there was a clear consensus with most experts
strongly disagreeing with that approach, as seen in Figure 3B.
The degree of agreement was signiﬁcantly less for patients
with remissions lasting only 12 to 24 months, as is seen in
Figure 3C.
CONSENSUS GUIDELINES FOR SALVAGE AUTOLOGOUS
HCT
The consensus committee agreed on the following
guideline statements:1. In transplantation-eligible patients relapsing after
primary therapy that did NOT include an autologous
HCT, high-dose therapy with autologous HCT as part of
salvage therapy should be considered standard.
2. High-dose therapy and autologous HCT should be
considered appropriate therapy for any patients re-
lapsing after primary therapy that includes an autol-
ogous HCTwith initial remission duration of more than
18 months.
3. High-dose therapy and autologous HCT can be used as
a bridging strategy to allogeneic HCT.
4. The role of postsalvage HCT maintenance needs to be
explored in the context of well-designed prospective
trials that should include new agents, such as mono-
clonal antibodies, IMiDs, and oral proteasome
inhibitors.
5. Autologous HCT consolidation should be explored as a
strategy to develop novel conditioning regimens or
post-HCT strategies in patients with short remission
(less than 18 months).
Figure 3. (A) Expert consensus on role of autologous HCT as consolidation therapy of an initial remission after ﬁrst autograft of greater than 24 months (0 strongly
agree and 10 strongly disagree, ordinate axis is the number of people who voted). (B) Expert consensus on role of autologous HCT as consolidation therapy of an initial
remission after ﬁrst autograft of less than 6 months (0 strongly agree and 10 strongly disagree, ordinate axis is the number of people who voted). (C) Expert consensus
on role of autologous HCT as consolidation therapy of an initial remission after ﬁrst autograft of between 12 and 24 months (0 strongly agree and 10 strongly disagree,
ordinate axis is the number of people who voted).
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deﬁne the role of salvage autologous HCT in patients
withMM relapsing after primary therapy comparing to
“best non-HCT” therapy.
The expert committee also underscored the importance
of collecting enough hematopoietic stem cells to perform 2
transplantations early in the course of the disease. This is
particularly important, as 30% of patients in the National
Cancer Research Institute (NCRI) Myeloma X Relapse trial
randomized to second autograft were unable to proceed to
HCT because of poor collection. Recently, the International
Myeloma Working Group wrote guidelines for mobilization,
suggesting that plerixafor could be used in patients who did
not have enough cells collected for a salvage HCT as a
mobilization strategy [44].
ROLE OF ALLOGENEIC HCT AS TREATMENT FOR PATIENTS
RELAPSING AFTER PRIMARY THERAPY RETROSPECTIVE
STUDIES
Most studies focusing on transplantation procedures as
salvage treatment strategies are separate evaluations of
either a second salvage autograft or a salvage allograft. Datafrom comparative studies are very few and limited by their
retrospective nature and/or their small study populations.
The largest registry analysis was performed by Freytes et al.
using data from the CIBMTR. The outcomes of a second
autotransplant (n¼ 137) were compared to those of a salvage
allograft (n ¼ 152) after nonmyeloablative or reduced-
intensity conditioning (NST/RIC) from 1995 to 2008. Non-
relapse mortality (NRM) at 1 year after transplantation was
higher in the NST/RIC cohort, 13% versus 2%. Three-year PFS
and OS for the NST/RIC cohort were 6% and 20%, respectively,
and inferior to the outcomes for the autologous trans-
plantation cohort (12% and 46%, respectively) [45]. These
results contrast with 2 recent donor versus no donor
analyses performed in patients relapsing after an initial
autograft. Patriarca et al. retrospectively analyzed 169
consecutive patients who had relapsed after an autograft and
had undergone HLA typing immediately after relapse. The
2-year NRM was 22% among the 75 patients who had an
identiﬁed HLA-compatible donor (donor group) versus 1%
for those without a donor (no donor group). The 2-year PFS
was 42% in the donor group and 18% in the no-donor group
(P < .0001) with similar 2-year OS of 54% and 53% for the
donor and no donor groups, respectively. Better response did
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mortality (TRM) in the donor group. An update of this study
is eagerly awaited to observe possible differences in OS with
longer follow up [46]. In another small donor versus no-
donor comparison, de Lavallade et al. showed that patients
with relapsed MM and an HLA-identical sibling who under-
went reduced-intensity allograft had a signiﬁcantly better
event-free survival than patients without an HLA-identical
sibling (46% versus 8% at 3 years) [47]. A small number of
single-institution comparison have also been performed and
are summarized in Table 4 [45-50].
Most reports of allografting as salvage therapy either after
ﬁrst-line autologous transplantation or after more lines of
therapies have been single-institution or registry analysis
and have been reviewed extensively elsewhere [51-53]. All
together, these studies showed the feasibility of allogeneic
transplantation in relapsed MM. However, given the het-
erogeneous patient cohorts and differences in conditioning
regimens and supportive care, its real role and curative po-
tential have not been clearly established.
At the recent meeting of the American Society of Hema-
tology in San Francisco (December 2014), Michallet et al. pre-
sented an EBMT registry study on allografting in MM, which
included 7333 patients who underwent transplantation at a
median age of 51 years between January 1990 and December
2012. Sixty-four percent of patients underwent trans-
plantation after the year 2004. The upfront use of an allograft
was observed to gradually decrease after the year 2000 to the
current 12%. Remarkably, an allograft was more frequently
used in recent years and, in 2012, most allografts, overall 33%,
were performed inpatientswho relapsed after a ﬁrst autograft.
This may suggest an overall preference in using an allograft at
ﬁrst relapse after a standard autograft. The 1588 patients who
received an allograft after a single autograft showed 5-year PFS
and OS of 26% and 33%, respectively, whereas the 930 who
received it after failing 2 lines of treatment showed 5-year PFS
and OS of 24% and 29%, respectively, and the 296 who un-
derwent transplantation with an allograft after at least 3 lines
of treatment showed 5-year PFS and OS of 15% and 23%,
respectively [54]. This report demonstrates the impact of lines
of therapy on allogeneic HCT outcomes, but also shows that a
small fraction of heavily pretreated patients can achieve long-
term disease control with allogeneic HCT.
Prospective Trials
Published prospective trials on the use of an allograft in
the setting of relapsed MM are very few. In a prospective
multicenter EBMT trial, Kröger et al. investigated the role
of allografting from unrelated donors in 49 patientsTable 4
Retrospective Comparisons of Autologous versus Allogeneic HCT for Patients Relap
Ref n NRM/RR PFS/OS Comments
[45] Auto: 137
Allo: 152
4%/91%
15%/83%
4%/29% at 5 yr
2%/9% at 5 yr
CIBMTR analysis only RIC conditio
[46] Auto: 94
Allo: 75%
1%/81%
22%/48%
18%/54% at 2 yr
42%/53% at 2 yr
Donor versus no donor analysis on
[47] Auto: 13
Allo: 19
0%/86%
33%/22%
8%/92% at 3 yr
46%/93% at 3 yr
Donor versus no donor analysis; R
[48] Auto: 42
Allo: 42
10%/72%
43%/33%
NS/54% at 3 yrs
NS/29% at 3 yrs
Ablative conditioning; case-match
[49] Auto: 26
Allo: 14
7%/NS
11%/NS
6.8 mo/29 mo
7.3 mo/13 mo
Retrospective not case controlled;
[50] Auto: 27
Allo: 19
3.7%/NS
5.3%/NS
19 mo/23 mo
6 mo/19 mo
Retrospective only ﬁrst relapse; m
RR indicates relapse rate; auto, autologous; allo, allogeneic.who relapsed after a previous autograft. Conditioning
regimen consisted of melphalan (140 mg/m2), ﬂudarabine
(90 mg/m2), and antithymocyte globulin (Fresenius)
(60 mg/kg body weight). All patients showed leukocyte and
platelet engraftment after a median of 15 days and 19 days,
respectively. Grades II to IV acute graft-versus-host disease
(GVHD) occurred in 25%, and 35% of the patients experi-
enced chronic GVHD. The overall response rate was 95%,
including 46% CR. The cumulative incidence of 1-year TRM
was 25% and was signiﬁcantly lower in transplantations
from fully HLA-matched donors compared with from mis-
matched donors (10% versus 53%, P ¼ .001). After a median
follow-up of 43 months, the 5-year PFS and OS were 20%
and 26%, respectively, and were signiﬁcantly better in
patients who achieved post-transplantation CR (41% versus
7%, P ¼ .04, and 56% versus 16%, P ¼ .02) [55].
The introduction of “new drugs” has made allografting a
less attractive treatment option because of its toxicity, at
least in newly diagnosed patients. However, the mechanisms
of actions of new drugs and immune-mediated graft-versus-
myeloma effects are not mutually exclusive. Kroger et al.
demonstrated that the addition of IMiDs or proteasome in-
hibitors to donor lymphocyte infusions after allogeneic HCT
could increase the frequency of CR. Thirty-two patients were
treated with donor lymphocyte infusions plus either an
IMiDs or bortezomib, if no response. Nineteen patients ach-
ieved CR by EBMT criteria, of which 17 had no evidence of
disease by ﬂow cytometric criteria and 15 by molecular
analysis [56]. Thus, continued exploration of post-
transplantation therapies with either IMiDs or proteasome
inhibitors may demonstrate a deﬁnite superiority of allog-
rafting as salvage therapy. Phase II trials exploring these
concepts have already been performed and are summarized
in Table 5.
Kröger et al. investigated a nonetotal body irradiation
myeloablative toxicity-reduced allograft consisting of intra-
venous busulfan (12.2 mg/kg) and cyclophosphamide (120
mg/kg) followed by maintenance therapy with lenalidomide
in 33 MM patients relapsing after an autograft. Median
remission duration after the autograft was 12 months. After
the allograft, 1-year cumulative incidence of TRM was only
6%. Twenty-four patients started maintenance therapy with
lenalidomide at a median dose of 5 mg for a median of 6
cycles. Cumulative incidence of relapse at 3 years was 42%
and the 3-year estimated probabilities of PFS and OS were
52% and 79%, respectively [57].
Two other reports have been published regarding the role
of post-RIC allogeneic HCT lenalidomide maintenance with
conﬂicting results. Kneppers et al. began 10 mg ofsing after an Initial Autograft
ning multiple lines of therapy
consecutive patients at ﬁrst relapse after auto HCT who had HLA typing.
IC conditioning; multiple lines of therapy
ed series
RIC conditioning
ultiple conditioning regimens
Table 5
Prospective Trials of IMiDS or Proteasome Inhibitors in Allografting
Ref Intervention, n NRM/RR PFS/OS Comment
[56] DLI only: 6
DLI þ IMiD and/or
bortezomib: 24
0%/NS CR pts: 58%/90% at 5 yr
No CR pt 35%/62% at 5 yr
59% CR by EBMT criteria; CR improved survival; 33% grade II-IV GVHD
[57] Lenalidomide 6%/42% 52%/79% at 3 yr 28% grades II-IV aGVHD
[58] Lenalidomide 30 10%/27% 63%/78% at 18 mo 30% aGVHD grades II-IV; 47% of all planned cycles completed; most common
dose upon completing study 5 mg QOD
[59] Lenalidomide NS/NS 61%/94% at 2 yr 37% aGVHD II-IV; 11% chronic extensive GVHD; only 10% of patients completed
planned therapy
[60] Bortezomib 25%/54% 30%/41% @ 3 yr 25% grade III aGVHD
[61] Bortezomib as part
of conditioning
16.9%/NS 74%/77% at 2 yr No post-transplantation maintenance in most patients
DLI indicates donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; QOD, every other day.
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patients with MM, of whom 30 were able to take the medi-
cation. Almost one half of the patients (47%) had to stop the
drug after 2 cycles because of the development of acute
GVHD. Notwithstanding, 37% of patients had a further
improvement in their MM response and the 1-year PFS from
start of maintenance was 69% [58]. Alsina et al. performed a
multicenter trial to determine the safety and toxicity of
maintenance lenalidomide after allogeneic HCT. Thirty pa-
tients with high-risk MMwere enrolled at 8 centers between
2009 and 2012. The median time from HCT to initiation of
lenalidomide maintenance was 96 days. Eleven patients
(37%) completed maintenance and 10 mg daily was the most
commonly delivered dose (44%). Most common reasons for
discontinuation were acute GVHD (37%) and disease pro-
gression (37%). As seen in the German and Dutch trials, acute
GVHD was seen in 38% of patients, NRM was 11%, with a PFS
of 63% at 3 years and an OS of 78% at 3 years [59]. These
results demonstrate that postallogeneic HCT lenalidomide
maintenance is feasible and results in further reduction of
MM tumor burden; however, whether this results in
improved long-term outcomes is uncertain.
Caballero-Velázquez et al. evaluated bortezomib within a
RIC and as maintenance after allografting in patients re-
lapsing after a prior autograft. The conditioning consisted of
ﬂudarabine (30 mg/m2 i.v. on days 9 to 5), melphalan (70
mg/m2 i.v. on days 4, 3), and bortezomib (1.3 mg/m2 i.v.
on day2); maintenance treatment consisted of cycles of i.v.
bortezomib (on days 1, 8, and 15). Sixteen patients were
prospectively enrolled. Nine of 16 (56%) and 5 of 16 (31%)
achieved CR and partial remission, respectively. Acute grade
III GVHD was observed in 25%. Nonhematological toxicities
consisted of peripheral neuropathy in 2 patients, liver
toxicity in 2, and pulmonary toxicity in 1. Three-year cu-
mulative incidences of TRM, relapse, and OS were 25%, 54%,
and 41% respectively [60].
Nishihori et al. explored a similar approach but as
consolidation of a ﬁrst remission. Twenty-two MM patients
with a very good partial response or better received ﬂudar-
abine (30 mg/m2 i.v. if with bortezomib and 40 mg/m2
i.v. when without bortezomib,  4 days) plus melphalan
(70 mg/m2 i.v.  2 days) with (n ¼ 13) or without (n ¼ 9)
bortezomib (1.3 mg/m2). The risk of moderate to severe
chronic GVHD at 2 years was 46% but the 2-year PFS was
74.8%, comparing favorably with the 52% 2-year PFS seen in
similar patients who underwent an autologous HCT [61].
In the light of these recent ﬁndings, 2 large cooperative
groups are planning phase II trials integrating bortezomib
into the conditioning regimens followed by some form ofpost-transplantation therapy, including either an IMiD or a
proteasome inhibitor. These trials will be offered as frontline
consolidation therapy of patients with high-risk disease or as
consolidation for ﬁrst relapse after an initial autograft.
There have been no prospective randomized trials of
allogeneic versus autologous HCT in the relapsed setting.
Recently, Gahrton et al. compared outcomes of patients who
relapsed on their upfront tandem autologous/reduced-
intensity allogeneic HCT (auto/RICallo) versus autologous
HCT. OS after progressionwas signiﬁcantly better in the auto/
RICallo group than in the autologous group (50% versus 27%
at 60months from time of progression). Salvage allograft was
performed at progression in 11 patients (17%) in the auto/
RICallo group and in 17 (8%) in the auto group. At last follow-
up, a preliminary analysis showed that 3 patients obtained
CR and 5 patients were alive; 2 in persistent CR in the among
patients who received a salvage allograft relapsing after an
auto/RICallo. Among the 17 patients who received an allo-
graft as salvage of an autograft relapse, 8 patients obtained
CR and 4 patients were alive, all in CRmore than 4 years after
salvage allogeneic HCT. These ﬁndings suggest that an allo-
graft is a valid option at progression after either upfront auto/
RICallo or an autograft [62].
CONSENSUS SURVEY REGARDING ROLE OF ALLOGENEIC
HCT IN RELAPSED MYELOMA
Before the consensus conference, the attendants were
asked to rate their agreement with a variety of statements
regarding salvage HCT, giving a score of 0 if they strongly
agreed with the statement and a score of 10 if they strongly
disagreed.
In contrast to the autologous setting, there was much
less consensus regarding the role of allografting for pa-
tients relapsing after autologous HCT, whatever the dura-
tion of remission. The results of the survey, when asked if
salvage allogeneic HCT should be considered for all patients
relapsing after primary therapy, if eligible, and with an
initial remission duration of more than 24 months, be-
tween 12 and 24 months, and less than 6 months, can be
seen in Figure 4A-C.
CONSENSUS GUIDELINES REGARDING ROLE OF
ALLOGENEIC HCT IN RELAPSED MYELOMA
The expert committee agreed on the following guideline
statements:
1. Allogeneic HCT should be considered appropriate
therapy for any eligible patient with early relapse (less
than 24 months) after primary therapy that included
Figure 4. (A) Expert consensus on role of allogeneic HCT as consolidation therapy of an initial remission after ﬁrst autograft of greater than 24 months (0 strongly
agree and 10 strongly disagree, ordinate axis is the number of people who voted). (B). Expert consensus on role of allogeneic HCT as consolidation therapy of an initial
remission after ﬁrst autograft between 12 and 24 months (0 strongly agree and 10 strongly disagree, ordinate axis is the number of people who voted). (C) Expert
consensus on role of allogeneic HCT as consolidation therapy of an initial remission after ﬁrst autograft of less than 6 months (0 strongly agree and 10 strongly
disagree, ordinate axis is the number of people who voted).
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cytogenetics, extramedullary disease, plasma cell leu-
kemia, or high lactate dehydrogenase) provided that
they responded favorably to salvage therapy before
allogeneic HCT.
2. Whenever possible, allogeneic HCT should be per-
formed in the context of a clinical trial.
3. The role of postallogeneic HCT maintenance therapy
needs to be further explored.
4. Prospective randomized trials need to be performed to
deﬁne the role of salvage allogeneic HCT in patients
with MM relapsing after primary therapy.
HCT FOR PATIENTS WITH REFRACTORY DISEASE
The Spanish myeloma group looked at the outcome of
outcome of primary refractory MM, which they deﬁned as
never having achieved a minimal response or better [63].
Patients underwent either tandem autologous or autologous
HCT followed by RIC allogeneic transplantation. Patients
progressing under induction therapy had shorter OS from
ﬁrst transplantation than the stable disease group. However,
induction therapy for all patients did not include any novel
agents but was with multiagent conventional chemotherapy.
In the Mayo series, 50 patients with primary refractory MM,
deﬁned as failure to achieve a partial response or greater,
were compared to 101 patients with chemosensitive disease.Twenty percent of the chemorefractory group achieved a CR
with the transplantation and had a 1-year PFS of 70% [64].
None of these patients received modern day therapy with
IMiDs and proteasome inhibitors.
A more contemporaneous analysis from the CIBMTR may
be more informative [65]. Five hundred ninety-three pa-
tients who underwent autologous HCTafter failing to achieve
less than partial remission to ﬁrst-line induction therapy
were identiﬁed. The patients were divided into 2 groups:
those who received additional salvage therapy and those
who did not before HCT. On multivariate analysis, there was
no impact of pretransplantation salvage on TRM, PFS, or OS,
thereby suggesting that those with suboptimal response to
induction could still derive a beneﬁt from high-dose
chemotherapy.KNOWLEDGE GAPS AND MOST COMPELLING QUESTIONS
The expert committee recognized that further random-
ized trials of the optimal type and timing of salvage HCT are
essential. Particularly, can patients relapsing after primary
therapy be risk stratiﬁed into high-risks groups, with pa-
tients with high-risk disease proceeding to more aggressive
salvage therapies, including allogeneic HCT, and patients
with very low-risk disease continued on maintenance ther-
apy without high-dose consolidation? The International
Myeloma Working Group is currently performing such an
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in the relapse setting.
Although recent data suggest that attaining a deep
response with primary therapy predicts prolonged response
before relapse, the impact of depth of response in the salvage
setting is less certain. The addition of new technologies, such
as ﬂow cytometry and deep gene sequencing, now allows for
monitoring and detection of minimal residual disease. How
this information will impact the treatment of patients re-
lapsing after primary therapy is still uncertain, but it will
likely guide us in deciding the intensity of salvage therapies
[66].
Likewise, the possibility that some cytogenetic or mo-
lecular subgroups may not beneﬁt from high-dose therapy
needs to be carefully explored. Pharmacogenomic predictors
of response to melphalan are currently under investigation
[67].
As the role of post-transplantation therapy has been well
established in the setting of frontline autologous HCT, the
expert committee recommended that prospective trials
exploring optimal postsalvage HCT maintenance therapy be
considered a priority, particularly those exploring novel
immunotherapy strategies postsalvage HCT (ie, vaccines,
cellular therapies, monoclonal antibodies, novel proteasome
inhibitors, histone deacetylase [HDAC] inhibitors, and
others). With the use of prolonged therapy after primary
therapy, such as maintenance, it will be critically important
to investigate novel agents and combinations to overcome
resistance to the agent used during maintenance (more
commonly lenalidomide, bortezomib, or even the combina-
tion). Novel conditioning regimens should also be explored
in this setting.
CURRENT PROTOCOL PORTFOLIO
Numerous trials are currently registered on the Clinical
Trials.gov website involving HCT in the salvage setting.
NCT01745588 aims to compare salvage HCT with pomalido-
mide/dexamethasone and clarithromycin as a maintenance
schedule against a non-HCT strategy of pomalidomide, clar-
ithromycin, and dexamethasone. NCT01242267 aims to
address the augmentation of high-dose melphalan with
increasing doses of thalidomide in a phase I/II setting.
NCT00938626 is aiming to utilize Bite antibodies to augment
T cell activation before salvage HCT in a phase I/II. The
Intergroupe Francophone du Myelome is conducting a phase
2 study (NCT02244125) for patients in ﬁrst relapse following
the IFM 2009/DFCI trial (VRD [bortezomib (velcade) lenali-
domide and dexamethasone] induction followed by upfront
or delayed HCT followed by a VRD consolidation and 1-year
lenalidomide maintenance). All patients are treated with the
combination of pomalidomide plus cyclophosphamide and
dexamethasone. The primary endpoint is response after 4
cycles. If patients are not progressive, they undergo an
autologous HCT if they did not get it upfront followed by
pomalidomide plus cyclophosphamide and dexamethasone
consolidation and pomalidomide plus dexamethasone
maintenance. The German-speaking multiple myeloma
study group currently enrolls patients in the “RELAPSE” trial,
comparing an early versus a late auto HCT in patients in
patients with 1 to 3 prior therapies (EudraCT 2009-013856-
61, ISRCTN 16345835).
The European Myeloma Network (EMN-alloRIC2010,
Eudra-CT number: 2010-018594-37, ClinicalTrials.gov Iden-
tiﬁer: NCT01460420) has a trial that aims at optimizing
clinical outcomes by including bortezomib in a melphalan-based conditioning regimen and using a combination of
bortezomib and lenalidomide as post-transplantation
maintenance. Candidates are high-risk myeloma patients,
younger than 70 years, with early relapse after ﬁrst primary
therapy with new drugs and autologous HCT.
The next NCRI myeloma trial is a randomized trial
exploring the role of an augmented melphalan conditioning
regimen by adding bortezomib followed by a second
randomization to either ixazomib or placebo for consolida-
tion and maintenance in patients relapsing after an initial
autograft.
The Blood and Marrow Transplant Clinical Trials Network
will perform a phase II randomized trial of ixazomib main-
tenance after allogeneic HCT. The conditioning regimen will
be melphalan-bortezomib. Both patients with high-risk
myeloma and in ﬁrst relapse after an autologous HCT will
be eligible.
There is an Medical Research Council study that is being
developed for relapsed disease after primary therapy.
CONCLUSIONS
Patients with relapsed MM have considerable options for
salvage treatment. Randomized trials are demonstrating
that, as with frontline therapy, depth of response to therapy
predicts outcomes. Thus, optimal use of high-dose therapy in
the salvage setting needs to be extensively explored through
well-designed prospective trials that include and explore
the newly developed agents for MM at different phases of
the HCT process (induction, conditioning, and maintenance).
In the meantime, both autologous and allogeneic HCT should
be considered valid clinical options based on this consensus
statement.
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